Department of Gastric Surgery, Cancer Hospital of China Medical University (Liaoning Cancer Hospital and Institute), No. 44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning 110042, China.
Can J Gastroenterol Hepatol. 2020 Jan 13;2020:9327868. doi: 10.1155/2020/9327868. eCollection 2020.
Primary duodenum lymphoma (PDL) is extremely rare with limited data available in the literature. In this study, we sought to describe clinical features and identify factors affecting survival in patients with PDL using a large population cohort.
The Surveillance, Epidemiology, and End Results (SEER) database was queried from 1998 to 2015.
A total of 1060 cases of PDLs were identified. Clinicopathological features as well as survival data of PDLs were analyzed and compared with 10573 primary gastric lymphomas (PGLs) and 3239 primary small intestinal lymphomas (PSILs) from the SEER database. PDL patients were younger in age (60.96 ± 15.205), and the proportion of stage I (53.21%) was higher in Ann Arbor staging. The proportion of PDLs treated by surgery (8.68%) is the lowest among PDLs, PGLs, and PSILs. The DSS of PDLs were significantly better than those of PGLs and PSILs, respectively (10-year survival rate: 21.24% vs. 20.40%, =0.027; 10-year survival rate: 21.24% vs. 16.79%, =0.001). Age, gender, Ann Arbor staging, and histological type were regarded as independent prognostic factor for the DSS by multivariate analysis (all < 0.05). Patients with <65 years, female, stage I, and FL were found to be significantly associated with good DSS. The treatment modality (surgery vs. conservative treatment) was not statistically related to DSS. The proportion of PDL patients who received surgical treatment gradually decreased from 15.60% in period 2 to 5.26% in period 4.
The clinicopathologic features of duodenal lymphoma were significantly different from those of gastric lymphoma and small intestinal lymphoma. The prognosis of PDLs was significantly better than those of the other two groups, and there was no statistical survival benefit from surgery in PDLs.
原发性十二指肠淋巴瘤(PDL)极为罕见,文献中可用的数据有限。本研究旨在通过大人群队列描述 PDL 患者的临床特征并确定影响生存的因素。
从 1998 年至 2015 年,我们查询了监测、流行病学和最终结果(SEER)数据库。
共确定了 1060 例 PDL 病例。分析了 PDL 的临床病理特征和生存数据,并与 SEER 数据库中的 10573 例原发性胃淋巴瘤(PGL)和 3239 例原发性小肠淋巴瘤(PSIL)进行了比较。PDL 患者年龄较轻(60.96±15.205),Ann Arbor 分期中 I 期比例较高(53.21%)。PDL 患者接受手术治疗的比例(8.68%)在 PDL、PGL 和 PSIL 中最低。PDL 的 DSS 明显优于 PGL 和 PSIL(10 年生存率:21.24%比 20.40%,=0.027;10 年生存率:21.24%比 16.79%,=0.001)。多因素分析显示,年龄、性别、Ann Arbor 分期和组织学类型是 DSS 的独立预后因素(均<0.05)。<65 岁、女性、I 期和 FL 的患者,DSS 明显较好。治疗方式(手术与保守治疗)与 DSS 无统计学相关性。接受手术治疗的 PDL 患者比例从第 2 期的 15.60%逐渐降至第 4 期的 5.26%。
十二指肠淋巴瘤的临床病理特征与胃淋巴瘤和小肠淋巴瘤明显不同。PDL 的预后明显优于后两者,且 PDL 手术治疗无明显生存获益。